Anavex Paves New Path for Alzheimer’s Treatment with Blarcamesine
Anavex Life Sciences, a publicly traded biopharmaceutical company, is advancing the field of neurodegenerative disease treatments, particularly Alzheimer’s disease, through its innovative drug candidate, blarcamesine (ANAVEX®2-73). With a focus on restoring cellular homeostasis via SIGMAR1 receptor activation, blarcamesine has demonstrated potential in slowing disease progression, offering hope for patients in the early stages of Alzheimer’s…
